Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

In this study of adults with BMI ≥25 kg/m2 and type 2 diabetes (n=834), the dual GLP-1 and glucagon receptor agonist cotadutide was associated with significant reductions in HbA1c and the 300mcg dose was associated with greater weight loss than liraglutide 1.8 mg at week 14.

SPS commentary:

The co-primary endpoints were changes in HbA1c and body weight at week 14. All doses of cotadutide tested were associated with statistically significant decreases in HbA1c from baseline to 14 weeks, when compared to placebo, with the greatest seen in the 300mcg dose group (–1.26 [95% CI –1.38, –1.14]). There were no differences in the HbA1c levels between the cotadutide dose groups and the liraglutide group (–1.30 [–1.45, –1.14]).

For body weight, statistically significant decreases from baseline to week 14 in percent change in body weight were observed in all dose groups. The change in the 300 mcg group (–5.01 [–5.57, –4.45]) was higher than that seen with liraglutide 1.8 mg (–3.44 [–4.20, –2.68]; P=0.001).

Diabetes Care